Navigation Links
Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals
Date:6/29/2009

we need to achieve profitability. Our growing customer base, centred on leading companies developing new antibody and protein therapeutics, provides us with a strong platform to build Gyros into a successful, profitable business. We are now in a position to invest in the increased commercial resources needed to market the key advantages of our unique Gyrolab systems to both existing and new customers as we seek to drive our top-line growth."

Gyrolab is a versatile, automated analytical platform that dramatically reduces the time required to optimize and execute immunoassays. This results in increased efficiency in process development and in clinical evaluation of therapeutic proteins. Applications span the entire spectrum for immunoassays and Gyrolab is now firmly established as the preferred solution for pharmacokinetic (PK) assays in the development of therapeutic proteins.

Per Carendi, CEO of SLS Invest, said, "We are very happy to have this opportunity to invest in Gyros. Erik and his management team have mapped out an exciting future for Gyros based on the real benefits that the Company's systems can deliver to developers of novel biotherapeutics. Given that biotherapeutics products are expected to play a significant role in the growth of the pharmaceutical industry as they are used in the treatment of an ever-increasing range of diseases, we are confident of Gyros' future success."

Notes to Editors:

About Gyros AB

Gyros is the world leader in automated micro-immunoassays for therapeutic protein development.

Gyrolab(R), the company's automated and open platform, is a versatile analytical tool that dramatically reduces the time required to optimize and execute immunoassays. Time for assay optimization is often cut from weeks to a matter of days. This results in increased efficiency in process development and in clinical evaluation of therapeutic proteins. T
'/>"/>

SOURCE Gyros AB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Pearl Therapeutics Raises $15.5 Million in Private Financing
2. Enobia Pharma Raises $40.1 Million Series B Financing
3. Cardiosolutions Raises $7 Million for Spacer Technology to Mitigate Mitral Regurgitation
4. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
5. VisEn Medical Raises $7 Million in Series B Financing
6. Thermo Fisher Scientific Reports Record Third Quarter Revenues and Adjusted EPS and Raises Full-Year Guidance
7. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
8. Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S
9. Perrigo Announces Final FDA Approval of Dexcels OTC Omeprazole; Raises Full Year Earnings Guidance
10. Anesiva Raises $45 Million in Common Stock Offering
11. Follica Raises $5.5 M To Advance New Treatment for Androgenetic Alopecia Into the Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... -- Heidrick & Struggles (Nasdaq: HSII ), the premier provider ... culture shaping worldwide, today  announced that John ... Healthcare and Life Sciences practice. As Global Practice ... a team of more than 80 partners, principals and associates ... Asia serving clients in the biopharmaceutical, medical ...
(Date:3/30/2015)... ROCKVILLE, Md. , March 30, 2015 ... company dedicated to the acquisition, development and commercialization of ... for the global market with a commercial focus on ... China Food and Drug Administration (CFDA) has approved the ... trial in ovarian clear cell carcinoma (OCCC) patients for ...
(Date:3/30/2015)... BELLINGHAM, Washington, USA (PRWEB) March 29, 2015 ... Europe and the United States and plenary talks by ... for SPIE Optics + Optoelectronics next month ... 700 technical presentations in 17 conferences alongside a two-day ... optics and photonics , the event will run 13-16 ...
(Date:3/30/2015)... MADISON, Wis. , March 30, 2015  FUJIFILM ... ("Fujifilm") and Cellular Dynamics International, Inc. (CEO: Robert ... leading developer and manufacturer of fully functioning human cells ... the two companies have entered into a definitive agreement ... offer to be followed by a second step merger. ...
Breaking Biology Technology:Heidrick & Struggles Strengthens Leadership of Healthcare - Life Sciences Practice 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 2Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 4Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 5Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 6Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 7Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 8
... Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") ... has dosed the first patient in its Phase ... University of California, San Diego ("UCSD"), ... Cysteamine") capsules in nephropathic cystinosis ("cystinosis"), a rare ...
... Interim Primary Endpoint Data from Phase II Study Shows 71% ... Docetaxel - , , - Secondary Endpoint Evaluation Shows ... Cohort - , , ORLANDO, Fla. and TUSTIN, Calif., ... ) today announced that preliminary results from a Phase II ...
... Clinical Oncology , , ORLANDO, Fla., June 1 ... use of ChemoFX(R), a chemosensitivity assay, to predict the ... of individual patients. Results from the study show ... percent were responsive to cetuximab, a result that is ...
Cached Biology Technology:Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 2Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 3Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 4Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 5Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 2Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 3Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 4Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 5Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 6Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 2Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 3
(Date:3/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has ... Market 2015-2019" report to their offering. ... grow at a CAGR of 23.5 percent over the ... scenario and the growth prospects of the Global Iris ... market size, the report considers the revenue generated from ...
(Date:3/23/2015)... , March 23, 2015   HOYOS Labs ... management company, today announced that the Company will demonstrate ... both enterprise and consumers at Connect:ID on March 23 ... HOYOS Labs will highlight the IEEE Biometric Open ... ; and enterprise access control system. BOPS was ...
(Date:3/20/2015)... , March 20, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... wallet is one of the products featured in 2015 ... 20th at 11:00 PM EST on the DIY Network. ... Las Vegas , site of the ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... of Virginia Health System have shown for the first ... in muscle cells can reverse myotonic dystrophy, the most ... About 40,000 people in the United States have myotonic ... progressive wasting of the muscles, irregular heartbeat, cataracts and ...
... device designed to "zap" away migraine pain before it starts ... people who suffer from the debilitating disease. , Results ... be effective in eliminating the headache when administered during the ... the Ohio State University Medical Center neurology investigators, was presented ...
... of the newest and most powerful tools of biomedical ... researchers have scored a dramatic success in the battle ... to use what are known as "small interfering RNAs" ... implanted in laboratory mice. Small interfering RNAs (siRNAs), first ...
Cached Biology News:Toxic molecule may cause most common type of muscular dystrophy 2Device effective in zapping the pain out of migraines 2RNA interference stops colon cancer spread in mice 2